On August 4, 2025, Tellgen Corporation announced plans to acquire 72.8630% of Wuhan HealthCare Biotechnology Co., Ltd. for RMB 291 million. Upon completion, HealthCare BIO will become a controlling subsidiary of Tellgen and be consolidated into its financial statements.
About HealthCare BIO
Headquartered in Wuhan’s Optics Valley Precision Medicine Industrial Base, HealthCare BIO is a high-tech enterprise specializing in precision diagnostics for cancer and cardiovascular diseases. The company integrates R&D, manufacturing, sales, and diagnostic services.
HealthCare BIO is a leader in molecular pathology, focusing on fluorescence in situ hybridization (FISH) and expanding into PCR-based diagnostics. It is committed to developing rapid, automated, and intelligent FISH solutions. Its core advantage is the proprietary FastProbe® rapid FISH probe preparation technology, which significantly improves efficiency and sensitivity compared with traditional FISH workflows.
The company has obtained multiple CE certifications, and its FISH products cover hematologic malignancies, solid tumors, bladder cancer, cervical cancer, and more. With sales in over 40 countries and regions, HealthCare BIO has established a mature international network and is recognized as a leading global brand in rapid FISH probes.
Strategic Significance
This acquisition allows Tellgen to complete its “Flow Fluorescence + PCR + FISH” full-chain oncology diagnostic strategy. HealthCare BIO’s products and R&D align with the IVD industry’s transformation trends of precision, service, and efficiency, and strengthen Tellgen’s capabilities in molecular pathology and intelligent diagnostic platforms.